Ultragenyx Pharmaceutical RARE Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's allocated share based compensation expense net of capitalized inventory cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's allocated share based compensation expense net of capitalized inventory cost?
- Ultragenyx Pharmaceutical (RARE) reported allocated share based compensation expense net of capitalized inventory cost of $30M in Q1 2026.
- How has Ultragenyx Pharmaceutical's allocated share based compensation expense net of capitalized inventory cost changed year-over-year?
- Ultragenyx Pharmaceutical's allocated share based compensation expense net of capitalized inventory cost decreased by 25.0% year-over-year, from $40M to $30M.
- What is the long-term trend for Ultragenyx Pharmaceutical's allocated share based compensation expense net of capitalized inventory cost?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's allocated share based compensation expense net of capitalized inventory cost has grown at a 9.9% compound annual growth rate (CAGR), from $104.95M to $153M.
- What does allocated share based compensation expense net of capitalized inventory cost mean?
- This represents the non-cash expense recognized for equity-based awards granted to employees and directors, adjusted for amounts capitalized into inventory. It reflects the cost of human capital compensation that does not impact immediate cash outflows. Investors use this to assess the true underlying operating expenses and potential dilution impact on shareholders.